y Chemex Pharmaceuticals Inc. hopes to file a new drug application(NDA) in August for Amlexanox for the treatment of aphthous ulcers,not an investigational new drug application as was reported in the May19 issue of BioWorld Today. Filing of the NDA would be the secondfor the Fort Lee, N.J., company, which got approval in September 1992for its lead compound, Actinex, to treat pre-malignant skin lesions.y Piper, Jaffray and Hopwood analyst George Dahlman inadvertentlyimplied that Calgene Inc. mothballed its entire Chicago operations inhis comments for a BioWorld Today article in the May 19 issue.Instead, he would like to state that the company scaled back its Chicagooperations and will now need to ramp up production.052094

(c) 1997 American Health Consultants. All rights reserved.